Encouraging Results for Eli Lilly's Schizophrenia Drug
Posted on: Monday, 3 September 2007, 15:15 CDT
A Phase II study has suggested that Eli Lilly's investigational schizophrenia drug has demonstrated efficacy without certain adverse effects generally associated with antipsychotics.
In the study - a randomized, double-blind, placebo-controlled clinical trial - patients were assigned to four weeks of treatment with either Lilly's investigational compound LY2140023; olanzapine, an atypical antipsychotic medication that targets dopamine and serotonin receptors as an active control; or placebo.
The study demonstrated that LY2140023 and olanzapine showed statistically significant improvement versus placebo in PANSS (Positive and Negative Syndrome Scale), the most common scale used for measuring symptoms of patients with schizophrenia. Both groups showed a rapid response, within one week.
However, treatment with LY2140023 was not observed to have certain adverse events that often occur with currently approved schizophrenia medications, including increased prolactin elevations, extrapyramidal symptoms (involuntary movements or muscle stiffness), or weight gain.
Overall, LY2140023 40mg given twice daily was found to be safe and well-tolerated, with most adverse events being mild-to-moderate in severity and not treatment-limiting.
"These data provide compelling new evidence that mGlu2/3 receptor agonists have antipsychotic properties and may provide a completely new therapeutic approach for treating schizophrenia and, perhaps, other neuropsychiatric disorders," said Steven Paul, Lilly's executive vice president of science and technology.
"Additional and longer-term studies are needed to confirm and extend these exciting initial findings. However, these data suggest that LY2140023 may provide a new alternative for the treatment of this often devastating condition."
Source: Datamonitor
Related Articles
- Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
- First-Episode Schizophrenia to Be Studied
- Nymox Announces Positive Results in New 2 Year Blinded, Placebo Controlled Study of NX-1207 for Benign Prostatic Hyperplasia
- Hythiam to Announce Urschel Double-Blind Placebo-Controlled Study Results on Thursday, November 1st
- Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
- Abraxis BioScience Presents Data From Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining Nab-Paclitaxel (ABRAXANE(R)) With Anti-Angiogenic Agents to Increase Tumor Response
- Acute and Immediate Impact of Hythiam's PROMETA(R) Protocols on Cravings and Cognition to Be Evaluated in Additional Double-Blind Placebo-Controlled Studies
- In Response to a Letter to the Editor That Appears in the Oct. 19, 2006, Issue of the New England Journal of Medicine, Eli Lilly and Company Provides the Following Statement:
- Debiopharm S.A. Presented Results of a Double-Blind Placebo-Controlled Study on First-in-Class Debio-025 in HIV-1-Infected Subjects
- Independent Double-Blind Placebo-Controlled Study Demonstrates Safety of Cold-Eeze in a Geriatric Population
 |
 |
User Comments (0)
RSS Feeds